Small Pharmaceuticals
Market Cap
₹2,195 ₹2,195 Cr.
P/E
18.90
PEG
1.70
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive if regulatory approvals convert into recurring orders, Sugammadex and Fulvestrant reach commercial manufacturing, and existing sterile capacity is filled.

The bull path depends on earlier commercialization and stronger manufacturing utilisation, while delays, underused capacity, tender weakness and price competition drive the bear path.

  • Venus Remedies
  • Syncom Formulations
  • Panacea Biotec

FAQs on Venus Remedies Ltd. Shareprice

Venus Remedies has given better returns compared to its competitors.
Venus Remedies has grown at ~52.36% over the last 8yrs while peers have grown at a median rate of 39.77%

Yes, Venus Remedies is expensive.
Latest PE of Venus Remedies is 20.53, while 3 year average PE is 14.25.
Also latest EV/EBITDA of Venus Remedies is 14.18 while 3yr average is 7.67.

Growth Table

  • Venus Remedies Ltd.
  • Syncom Formulations
  • Panacea Biotec

Balance Sheet

  • Venus Remedies Ltd.
  • Syncom Formulations
  • Panacea Biotec

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Venus Remedies Ltd.
  • Syncom Formulations
  • Panacea Biotec

Cash Flow

  • Venus Remedies Ltd.
  • Syncom Formulations
  • Panacea Biotec

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Venus Remedies Ltd.
  • Syncom Formulations
  • Panacea Biotec

Quarterly Results

  • Venus Remedies Ltd.
  • Syncom Formulations
  • Panacea Biotec

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Venus Remedies Ltd. Financials

Balance sheet of Venus Remedies is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Venus Remedies is increasing.
Latest net debt of Venus Remedies is -₹59.03 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹158.4 Crs.

Yes, profit is increasing.
The profit of Venus Remedies is ₹116 Crs for TTM, ₹103 Crs for Mar 2026 and ₹45.31 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Venus Remedies latest dividend payout ratio is 13.0% and 3yr average dividend payout ratio is 13.0%

Companies resources are majorly tied in miscellaneous assets

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech